Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 1:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 176 matching trials from the live ClinicalTrials.gov search.
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Beverly Hills, California • Glendale, California + 17 more
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX, Anti-VEGF
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
Conditions
Choroidal Neovascularization, Wet Macular Degeneration
Interventions
ICON-1, aflibercept
Biological
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
77
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Active, not recruiting No phase listed Observational Accepts healthy volunteers

GARM II: A Study on the Genetics of Age-related Maculopathy

NCT01115387
Conditions
Age-related Macular Degeneration, Age-related Maculopathy
Interventions
Observational-1, Observational-2
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
49 Years and older
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Conditions
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Interventions
Faricimab, OLN324
Drug
Lead sponsor
Ollin Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more
Conditions
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Conditions
Macular Degeneration
Interventions
NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Conditions
Wet Age Related Macular Degeneration, Wet AMD
Interventions
NT-101 Low Dose, NT-101 High Dose
Drug
Lead sponsor
NexThera Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Rosedale, Maryland • Durham, North Carolina • Erie, Pennsylvania + 1 more
Conditions
Neovascular Macular Degeneration
Interventions
Aflibercept
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
bevacizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Conditions
Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
Interventions
ranibizumab
Drug
Lead sponsor
Anne Fung MD
Other
Eligibility
50 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Conditions
Neovascular Wet Age-related Macular Degeneration (AMD)
Interventions
REGN2176-3
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Beverly Hills, California • Colorado Springs, Colorado • Boston, Massachusetts + 1 more
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Study-specific rehabilitation (SSR) procedures
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Neovascular (Wet) Age-related Macular Degeneration
Interventions
SKG0106
Genetic
Lead sponsor
Skyline Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
Conditions
Neovascular Age-related Macular Degeneration
Interventions
SKG0106
Genetic
Lead sponsor
Skyline Therapeutics (US) Inc.
Industry
Eligibility
50 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
St. Petersburg, Florida • Boston, Massachusetts • Katy, Texas + 1 more
Conditions
Dry Age-related Macular Degeneration
Interventions
Risuteganib, Sham
Drug · Other
Lead sponsor
Allegro Ophthalmics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 4 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Thickness Module

NCT04428242
Conditions
Macular Edema, Macular Degeneration
Interventions
RHMS-RTM, SD-OCT
Device · Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sacramento, California